Clincosm LogoSign in Get a demo

Psoriatic Arthritis

Showing 51 - 75 of 291
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Korean Post-marketing Surveillance for Xeljanz

Completed
  • Rheumatoid Arthritis
  • Psoriatic Arthritis
    • Chonju, Chonbuk, Korea, Republic of
    • +48 more
    Sep 9, 2022

    s of Chronic Inflammatory Systemic Diseases

    Recruiting
    • Inflammatory Bowel Diseases
    • +7 more
      • Besançon, France
        Charline Vauchy
      Sep 2, 2022

      Psoriatic Arthritis Trial in Worldwide (SUNPG18_07 I, SUNPG18_07 II, SUNPG18_07 III)

      Active, not recruiting
      • Psoriatic Arthritis
      • SUNPG18_07 I
      • +2 more
      • Glendale, Arizona
      • +82 more
      Aug 26, 2022

      Medication Adherence in Psoriatic Arthritis

      Completed
      • Psoriatic Arthritis
      • Disease activity in psoriatic arthritis (DAPSA)
      • +5 more
      • Istanbul, Fatih, Turkey
        Bezmialem Vakif University
      Aug 26, 2022

      Psoriatic Arthritis Trial in United States (ATI-450, Placebo Oral Tablet)

      Recruiting
      • Psoriatic Arthritis
      • Miami Lakes, Florida
      • +7 more
      Aug 19, 2022

      Accelerometry in Follow up of Arthritis - a Pilot Study

      Recruiting
      • Arthritis, Rheumatoid
      • +2 more
      • Akcelerometry follow up
      • Forde, Vestlandet, Norway
        Pawel Mielnik
      Aug 15, 2022

      Psoriatic Arthritis Trial in Worldwide (Deucravacitinib, Placebo)

      Recruiting
      • Psoriatic Arthritis
      • Jonesboro, Arkansas
      • +127 more
      Aug 12, 2022

      Psoriatic Arthritis Trial in Australia, Spain, United States (TILD sub-cutaneous (SC) injection)

      Active, not recruiting
      • Psoriatic Arthritis
      • TILD sub-cutaneous (SC) injection
      • Covina, California
      • +30 more
      Aug 5, 2022

      Evaluate Safety and Efficacy of Cosentyx in Pediatric PsV, PsA,

      Recruiting
      • Psoriasis Vulgaris
      • +2 more
      • Cosentyx
      • Nagoya-city, Aichi, Japan
      • +23 more
      Aug 3, 2022

      Psoriatic Arthritis Trial in Worldwide (Deucravacitinib, Placebo, Apremilast)

      Recruiting
      • Psoriatic Arthritis
      • Birmingham, Alabama
      • +136 more
      Jul 29, 2022

      Discovery of Arthritis in Psoriasis Early Rheumatological

      Completed
      • Psoriasis
      • +3 more
      • cutaneous parameters of psoriasis (exposure)
      • +6 more
      • Nijmegen, Netherlands
        Radboudumc
      Jul 28, 2022

      Psoriatic Arthritis, Spondylitis, Sacroilitis Trial in Germany (Tofacitinib 5 MG Oral Tablet [Xeljanz], Placebo oral tablet)

      Recruiting
      • Psoriatic Arthritis
      • +2 more
      • Tofacitinib 5 MG Oral Tablet [Xeljanz]
      • Placebo oral tablet
      • Berlin-Steglitz, Germany
      • +18 more
      Jul 23, 2022

      Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis Trial in Worldwide (Bimekizumab,

      Completed
      Has Results
      • Chronic Plaque Psoriasis
      • +2 more
      • San Diego, California
      • +76 more
      Jul 15, 2022

      Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis Trial in Worldwide (Bimekizumab,

      Completed
      Has Results
      • Chronic Plaque Psoriasis
      • +2 more
      • Phoenix, Arizona
      • +104 more
      Jul 15, 2022

      Covid-19 Infection, Rheumatoid Arthritis, Psoriatic Arthritis Trial in Edmonton (Hydroxychloroquine/Chloroquine)

      Active, not recruiting
      • Covid-19 Infection
      • +3 more
      • Hydroxychloroquine/Chloroquine
      • Edmonton, Alberta, Canada
        University of Alberta
      Jul 19, 2022

      Psoriatic Arthritis Trial in Germany (Secukinumab, Ustekinumab)

      Recruiting
      • Psoriatic Arthritis
      • Secukinumab
      • Ustekinumab
      • Frankfurt, Hesse, Germany
      • +36 more
      Jul 20, 2022

      Monitoring of Inflammatory Conditions

      Recruiting
      • Inflammatory Disease
      • +8 more
      • Questionnaire
      • Semi-structured interview
      • Nottingham, Nottinghamshire, United Kingdom
        University of Nottingham
      Jul 11, 2022

      Psoriatic Arthritis Trial in Worldwide (NDI-034858, Placebo)

      Recruiting
      • Psoriatic Arthritis
      • Palm Desert, California
      • +23 more
      Jun 29, 2022

      Yuflyma® (Adalimumab), Patient Experience After Switching

      Recruiting
      • Rheumatoid Arthritis
      • +5 more
      • Marseille, France
      • +1 more
      Jun 17, 2022

      Sub-cutaneous Infliximab in Inflammatory Rheumatic Disease

      Not yet recruiting
      • Rheumatoid Arthritis
      • +2 more
      • collection of clinical parameters and blood sample
      • Paris, IDF, France
        Rheumatology Department, Cochin Hospital
      Jun 17, 2022

      Survey About Diet in Chronic Inflammatory Rheumatic Diseases

      Active, not recruiting
      • Rheumatic Disease
      • +8 more
      • Questionnaire
      • Poitiers, Nouvelle Aquitaine, France
        CHU Poitiers
      Jun 11, 2022

      Psoriatic Arthritis Trial in Worldwide (Apremilast 20mg, Apremilast 30mg, Placebo)

      Completed
      Has Results
      • Psoriatic Arthritis
      • Apremilast 20mg
      • +2 more
      • Phoenix, Arizona
      • +117 more
      May 26, 2022

      Abatacept in Sweden Using Swedish Rheumatology Quality Register

      Active, not recruiting
      • Rheumatoid Arthritis
      • Psoriatic Arthritis
        • Princeton, New Jersey
          Local Institution
        Jun 7, 2022

        Systemic Lupus Erythematosus, Sjogren's Syndrome, Inflammatory Myositis Trial in Rochester (mRNA COVD19 vaccine)

        Terminated
        • Systemic Lupus Erythematosus
        • +7 more
        • mRNA COVD19 vaccine
        • Rochester, Minnesota
          Mayo Clinic in Rochester
        May 31, 2022

        Rheumatoid Arthritis, Psoriatic Arthritis Trial in Oxford (Nanobubble drink)

        Withdrawn
        • Rheumatoid Arthritis
        • Psoriatic Arthritis
        • Nanobubble drink
        • Oxford, United Kingdom
          Oxford University Hospitals NHS Trust
        May 17, 2022